Sec. 902. Co-prescribing opioid overdose reversal drugs grant program
784 words·~4 min read·
/bill/114/hr/4435/ih/section-902·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Not later than six months after the date of the enactment of this Act, the Secretary of Health and Human Services shall establish, in accordance with this section, a four-year co-prescribing opioid overdose reversal drugs grant program (in this title referred to as the grant program ) under which the Secretary shall provide not more than a total of 12 grants to eligible entities to carry out the activities described in subsection (c). For purposes of this section, the term eligible entity means a federally qualified health center (as defined in section 1861(aa) of the Social Security Act ( 42 U.S.C. 1395x(aa) )), an opioid treatment program under part 8 of title 42, Code of Federal Regulations, or section 303(g) of the Controlled Substances Act ( 21 U.S.C. 823(g) ), a program approved by a State substance abuse agency, or any other entity that the Secretary deems appropriate.
For purposes of this title, the term co-prescribing means, with respect to an opioid overdose reversal drug, the practice of prescribing such drug in conjunction with an opioid prescription for patients at an elevated risk of overdose, or in conjunction with an opioid agonist approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) for the treatment of opioid abuse disorders, or in other circumstances in which a provider identifies a patient at an elevated risk for an intentional or unintentional drug overdose from heroin or prescription opioid therapies.
For purposes of the previous sentence, a patient may be at an elevated risk of overdose if the patient meets the criteria under the existing co-prescribing guidelines that the Secretary deems appropriate, such as the criteria provided in the Opioid Overdose Toolkit published by the Substance Abuse and Mental Health Services Administration. To be eligible to receive a grant under this section, an eligible entity shall submit to the Secretary of Health and Human Services, in such form and manner as specified by the Secretary, an application that describes— the extent to which the area to which the entity will furnish services through use of the grant is experiencing significant morbidity and mortality caused by opioid abuse; the criteria that will be used to identify eligible patients to participate in such program; and how such program will work to try to identify State, local, or private funding to continue the program after expiration of the grant.
An eligible entity receiving a grant under this section may use the grant for any of the following activities: To establish a program for co-prescribing opioid overdose reversal drugs, such as naloxone. To train and provide resources for health care providers and pharmacists on the co-prescribing of opioid overdose reversal drugs. To establish mechanisms and processes, consistent with applicable Federal and State privacy rules, for tracking patients participating in the program described in paragraph
(1)and the health outcomes of such patients. To purchase opioid overdose reversal drugs for distribution under the program described in paragraph (1). To offset the co-pays and other cost sharing associated with opioid overdose reversal drugs to ensure that cost is not a limiting factor for eligible patients. To conduct community outreach, in conjunction with community-based organizations, designed to raise awareness of co-prescribing practices, and the availability of opioid overdose reversal drugs. To establish protocols to connect patients who have experienced a drug overdose with appropriate treatment, including medication assisted treatment and appropriate counseling and behavioral therapies. As a condition of receipt of a grant under this section, an eligible entity shall, for each year for which the grant is received, submit to the Secretary of Health and Human Services information on appropriate outcome measures specified by the Secretary to assess the outcomes of the program funded by the grant, including— the number of prescribers trained; the number of prescribers who have co-prescribed an opioid overdose reversal drugs to at least one patient; the total number of prescriptions written for opioid overdose reversal drugs; the percentage of patients at elevated risk who received a prescription for an opioid overdose reversal drug; the number of patients reporting use of an opioid overdose reversal drug; and any other outcome measures that the Secretary deems appropriate. For each year of the grant program under this section, the Secretary of Health and Human Services shall submit to the appropriate committees of the House of Representatives and of the Senate a report aggregating the information received from the grant recipients for such year under subsection
(d)and evaluating the outcomes achieved by the programs funded by grants made under this section. There is authorized to be appropriated to carry out this section and section 903 $4,000,000 for each of fiscal years 2017 through 2021.
Connectionstraces to 3
Traces to 3 documents
Citation graph
cites case law
Sec. 902
Co-prescribing opioid overdose reversal drugs grant program
Cites 3Cited by 0 across 0 sources